BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 11, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2000

View Archived Issues

CV Therapeutics reports potential strategy for raising HDL cholesterol

Read More

Targeted Genetics forms new company based on cell therapy technology

Read More

Initial phase I results show good safety for Antrin photoangioplasty

Read More

SmithKline Beecham launches Paxil in Japan

Read More

Expert committee recommends continuation of Remune trial in Spain

Read More

Schering and MediGene begin HPV vaccine trial

Read More

Company Profile: Micromet

Read More

Baxter's new recombinant hemophilia therapy enters phase III

Read More

Oral bosentan effective as pulmonary hypertension therapy

Read More

AlphaGene identifies two genes associated with Alzheimer's disease

Read More

Irbesartan to be evaluated in clinical trial for new indication: heart failure

Read More

Update on proposed merger of Cambridge NeuroScience and CeNeS; Moraxen launched

Read More

Tripep presents first clinical results for novel anti-HIV agent with a new mode of action

Read More

CCI-779: a new rapamycin analogue targeting mTOR with a promising clinical profile

Read More

ACUTE II results presented at AHA sessions

Read More

D-Pharm and Nycomed Amersham begin imaging agent collaboration

Read More

Moenomycin degradation products and synthetic analogues studied at Advanced Medicine

Read More

PDE4 inhibitor YM-976 is first to show dissociation between antiinflammatory activity and emesis

Read More

Promising anxiolytic candidate under joint development by CoCensys and Wyeth-Ayerst

Read More

Use of new benzodiazepine derivatives for imaging thrombi

Read More

Novel ester of sPLA2 inhibitor has improved oral bioavailability

Read More

New melatonin derivatives and analogues for inducing sedation described in recent patent

Read More

Novel antiarrhythmic agents under study at Mochida

Read More

Sodium channel blockers and their use in the treatment of pain disclosed by Mochida

Read More

Uniroyal's potent new anti-HIV agents retain activity against strains carrying RT mutations

Read More

New oxytocin antagonists in development at Ferring for use in preterm labor, menstrual pain

Read More

Recent patent describes synthesis and use of indazole derivatives acting as 5-HT3/5-HT4 antagonists

Read More

NPY receptor ligands synthesized at Meiji Seika reduce food intake in animals

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 10, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Brenig Therapeutics discovers new LRRK2 inhibitors

    BioWorld Science
    Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing